Taldalafil

Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor recognized for its role in supporting erectile function and managing benign prostatic hyperplasia. By inhibiting PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), tadalafil promotes smooth muscle relaxation and vasodilation within the corpus cavernosum. Distinguished by a prolonged terminal half-life of approximately 17.5 hours, tadalafil enables extended therapeutic windows and once-daily dosing potential. Tadalafil’s pharmacological properties have led to significant interest in research settings exploring vascular function, endothelial biology, and urological disorders. Its efficacy in enhancing erectile performance without the need for continuous stimulation makes it a subject of ongoing investigation for broader applications beyond sexual health.

This product is intended solely for laboratory research use and is not approved for human or veterinary applications, diagnostic procedures, therapeutic uses, or consumption. All products are sold under the condition that they will be handled exclusively by qualified individuals familiar with their use and potential risks. Any application of this material in humans or animals for therapeutic or diagnostic purposes must comply with the regulations established in 21 CFR 312 and 21 CFR 600.